Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma GmbH
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin (3000 U anti-Xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic events in acutely ill medical patients
The primary objective is to confirm that certoparin is non-inferior in preventing the primary endpoint consisting of proximal deep vein thrombosis (DVT), symptomatic non-fatal pulmonary embolism (PE) ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different breakfast conditions over two weeks
To demonstrate that Ritalin® LA has comparable efficacy after a very light breakfast compared to a standard continental breakfast in children with ADHD after treatment for one week assessed by weekly ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase
To demonstrate that zoledronic acid has superior efficacy compared with placebo on the percent change of bone mineral density (BMD) as assessed by the T-score at lumbar spine and total hip region at m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonvalvular atrial fibrillation
Primary objective is to document the feasibility and safety of short-term treatment with a fixed, body weight-independent certoparin regimen (8000 U anti-Xa twice daily) in patients with persistent no...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A 12-month, two-armed, randomized, double-masked, multicenter, Phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period
The primary objective of this study is to demonstrate superiority of an adjunctive treatment of laser photocoagulation to Ranibizumab 0.5 mg as intravitreal injection in the mean change in BCVA from b...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Neoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment with Letrozole (2.5 mg/day) with or without Zoledronic acid (4 mg every 4 weeks)
Primary objective of the study is to demonstrate superiority of letrozole and zoledronic acid over letrozole monotherapy given as 6 months preoperative treatment with respect to tumor response. Respon...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Everolimus in patients with metastatic renla cell carcinoma previously treated with sunitinib or pazopanib
The primary objective of the study is to assess the efficacy of everolimus in patients with metastatic renal cell cancer whose disease progressed on or after prior first-line treatment with sunitinib ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately responding to a 5 week therapy with ramipril 5 mg and felodipine 5 mg
To demonstrate that 5 weeks of treatment with valsartan 160 mg plus amlodipine 10 mg provide an additional mean sitting systolic blood pressure reduction in patients not adequately responding to 5 wee...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sandostatin® LAR® and pegvisomant, in acromegalic patients only partially responsive to somatostatin analog monotherapy
The primary objective of this study is to demonstrate the ability of a combination therapy with Sandostatin LAR and Cabergoline to reduce GH and IGF-I levels in acromegalic patients that are only par...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin inhibitor (Sandimmun® Optoral or Prograf®) in stable renal transplant patients
The primary objective of this trial is to show superiority of a CNI-free regimen with respect to renal function assessed by glomerular filtration rate (GFR) – Nankivell method – at Month 12 as compare...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next